Alerta

USING VEFG165 FRAGMENTS AS A NOVEL BIOMARKER OF INFLAMMATION TO DIAGNOSE AND GUIDE MEDICAL CARE AND TREATMENTS

Resumen de: US20260308202A1

Described herein are peptides and pharmaceutical compositions, e.g., for the treatment of inflammation. Further described herein are methods of treating patients for inflammation and/or infection with particularly efficacious treatments depending on the subject's level of fVEGF.

PREDICTION OF PREECLAMPSIA RISK USING CIRCULATING, CELL-FREE RNA

Resumen de: EP4818331A2

0001 The disclosure describes changes in cfRNA gene expression that are associated with risk for preeclampsia. Accordingly, the disclosure provides methods and kits for preeclampsia risk assessment.

サーバ装置、分析方法、及びプログラム

Resumen de: US20260224206A1

0000 An excrement analysis apparatus includes an inputter, a memory, a first analyzer, and a second analyzer. The inputter inputs imaging data captured by an image capture apparatus installed in such a way as to include, in a capturing range, an excretion range of excrement in a toilet bowl of a toilet. The memory temporarily holds the imaging data input by the inputter. The first analyzer analyzes first analysis target data being the imaging data input by the inputter, and outputs notification information to an observer who observes a user of the toilet. The second analyzer analyzes second analysis target data being the imaging data that is input by the inputter and temporarily held by the memory, and outputs detailed information indicating a content of excretion.

An ink formulation

Resumen de: GB2705330A

An ink for a screen-printed electrode comprises gold microstructures with a maximum dimension of 0.05-7.5 microns and a polymer dissolved or dispersed in one or more solvents having a boiling point of >110C. The ink may comprise 7.5-25 wt.% gold microstructures, 4-15 wt.% polymer, and 45-65 wt.% solvent. The gold microstructures may be microspheres or microflakes. The polymer may comprise polyethylene terephthalate, polyethyloxazoline, polymethylmethacrylate, polyacrylates, polyesters, polyamines, polyethers, polyvinyl acetate, polyvinyl chloride, polyhydroxyethers, cellulose derivatives, or poly(lactide). The solvent may be alpha-terpineol, di(propylene glycol) methyl ether, or propylene glycol monomethyl ether acetate. A method of making an electrode comprises screen-printing a working electrode onto a substrate using the ink and providing reference and counter electrodes on the substrate. A method of detecting a target analyte in a sample comprises contacting the electrode with the sample, wherein a response characteristic of the electrode is capable of being operably varied, thereby indicating the presence of the analyte. No Figure

PHARMACEUTICAL PREPARATION FOR DIAGNOSING AND TREATING ALZHEIMER'S DISEASE

Resumen de: EP4818330A1

The present invention relates to the field of biomedicine. Provided are a marker that can be used for early diagnosis of Alzheimer's disease, and the use thereof. Specifically provided is a marker for early diagnosis of Alzheimer's disease. The marker is a Maf1 gene or the protein rhereof. High expression of the Maf1 gene or the protein thereof in neuronal cells indicates that a subject is at high risk of developing Alzheimer's disease. The method provides a new diagnostic and therapeutic target for AD.

Ｍ２マクロファージ分化誘導促進剤

Resumen de: JP2026158933A

【課題】皮膚における血管周囲のマクロファージの性質、及び当該マクロファージが血管や皮膚性状に与える影響を明らかにし、新規作用機序に基づく有用な製剤を提供することを課題とする。【解決手段】本発明者らは、誠意研究の結果、皮膚において、毛細血管周囲にＭ２マクロファージが取り囲むように存在すること、Ｍ２マクロファージの培養上清を、血管内皮細胞に添加すると、血管安定化が促進することを発見した。そこで、Ｍ２マクロファージ分化誘導を促進する化粧料素材を探索し、アカツメクサ花エキス、モモ葉エキス、及びアセロラ種子エキスからなる群から選ばれる１又は複数のエキスを含む、Ｍ２マクロファージ分化誘導促進剤、Ｍ２マクロファージ分化誘導促進を介した血管安定化剤、Ｍ２マクロファージ分化誘導促進を介した美白剤を提供する。【選択図】図４

COMPOSITIONS AND METHODS FOR INCREASING OR ENHANCING TRANSDUCTION OF GENE THERAPY VECTORS AND FOR REMOVING OR REDUCING IMMUNOGLOBULINS

Resumen de: AU2019306121A1

Disclosed herein are methods for treating patients that may develop or already have pre- existing gene therapy neutralizing antibodies by administering a protease that cleaves peptide bonds present in immunoglobulins or by administering a glycosidase that cleaves carbohydrate residues present on immunoglobulins, or other similar enzymatic cleavage of immunoglobulins in vivo. Also disclosed are methods for utilizing IdeS and other immunoglobulin G-degrading enzyme polypeptides for gene therapy treatment of a disease in a patient in need thereof.

ＧＤＦ－１５結合核酸分子、ＧＤＦ－１５を検出するためのキット、及びＧＤＦ－１５を検出するための方法

Resumen de: JP2026156851A

【課題】 本開示は、ＧＤＦ－１５に対する優れた結合能を有する核酸分子を提供する。【解決手段】 本開示のＧＤＦ－１５結合核酸分子は、（ａ１）配列番号７の塩基配列を含み、且つ、ＧＤＦ－１５に結合するポリヌクレオチド、（ａ２）配列番号７の塩基配列において１若しくは数個の塩基が欠失、置換、挿入、及び／又は付加された塩基配列を含み、且つ、ＧＤＦ－１５に結合するポリヌクレオチド、又は（ａ３）配列番号７の塩基配列に対して８０％以上の同一性を有する塩基配列を含み、且つ、ＧＤＦ－１５に結合するポリヌクレオチドを含み、配列番号７の塩基配列において下線で示されるＴは、チミン塩基又は修飾チミン塩基である。【選択図】 図９

抗ＭＣＴ１抗体およびその使用

Resumen de: AU2019205489A1

This invention generally pertains to antibodies and antigen-binding fragments thereof, e.g., humanized, chimeric, and human antibodies and antigen-binding fragments thereof, and fusion proteins, compositions containing such antibodies and antigen-binding fragments thereof and fusion proteins, wherein such antibodies and antigen-binding fragments thereof and fusion proteins specifically bind to MCT1, e.g., human or non-human MCT1 and antagonize, inhibit or block one or more MCT1-associated functions

一种验证吴茱萸碱改善D-gal诱导衰老认知及运动功能障碍的方法

Resumen de: CN122849250A

0001 本发明公开了一种验证吴茱萸碱改善D‑gal诱导衰老认知及运动功能障碍的方法，属于医学方法验证技术领域。选择雄性小鼠，并分为对照组、D‑半乳糖模型组、DFMO干预组、吴茱萸碱干预组；进行新行为学测试后处理小鼠；分别取每组小鼠眼球血进行血清生化检测；采集组织样本，采用BCA法测定蛋白浓度后，再进行免疫组织化学与免疫荧光测试，而后再进行代谢物检测；培养、处理细胞后进行siRNA转染，进行分子对接评估吴茱萸碱与ODC1的结合能力及相互作用模式；最后分析统计结果。本发明发现吴茱萸碱可显著改善衰老小鼠认知和运动功能障碍，降低脑组织尿素水平，下调尿素循环关键酶表达，抑制P53表达。

原形質膜アンカー型プロテアーゼを利用するための系および方法

Resumen de: WO2025059015A1

Described herein is a system comprising a eukaryotic cell, wherein the eukaryotic cell comprises: a plasma membrane polypeptide coupled to a transcription factor by a linker, wherein the linker comprises a protease cleavable site; and a plasma membrane anchored protease; wherein the plasma membrane anchored protease is capable of cleaving the linker. The system can further include a reporter construct, wherein the transcription factor can bind to a promoter of the reporter construct to indicate an ability of the plasma membrane polypeptide to traffic to the plasma membrane.

ANTIBODIES RECOGNIZING TAU

Resumen de: MX2026009889A

The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.

Aβ1-42抗体及其制备方法和应用

Resumen de: WO2026199818A1

The present application provides a method for preparing a humanized Aβ1-42 antibody and use thereof. Specifically, the antibody of the present application combines a murine antibody variable region and a human antibody framework region; on the basis of specifically binding to an Aβ peptide segment, the antibody reduces immunogenicity due to its humanized framework region. The antibody has the advantages of high affinity, high specificity, low immunogenicity, and scalability for large-scale production. The antibody of the present application can be used for detecting an Aβ1-42 antigen, eliminating Aβ deposits, or treating related diseases thereof, such as Alzheimer's disease.

抗Aβ1-40抗体及其制备方法和应用

Resumen de: WO2026199817A1

The present application provides a method for preparing a humanized Aβ1-40 antibody and use thereof. Specifically, the antibody of the present application combines a murine antibody variable region and a human antibody framework region; on the basis of specifically binding to an Aβ peptide segment, the antibody reduces immunogenicity due to its humanized framework region. The antibody has the advantages of high affinity, high specificity, low immunogenicity, and scalability for large-scale production. The antibody of the present application can be used for detecting an Aβ1-40 antigen, eliminating Aβ deposits, or treating related diseases thereof, such as Alzheimer's disease.

靶向TSLP和IL-4/IL-4R的双功能融合蛋白及其应用

Resumen de: CN122872563A

0001 本公开属于生物医药领域，具体涉及靶向TSLP和IL‑4/IL‑4R的双功能融合蛋白及其应用。本公开的双功能融合蛋白对IL‑4R、IL‑4和/或TSLP具有较好的亲和力和/或生物学活性，可用于检测IL‑4R、IL‑4和/或TSLP、诊断或防治与IL‑4R、IL‑4和/或TSLP相关的疾病或病症。

Hyperspectral Image-Guided Ocular Imager for Alzheimer's Disease Pathologies

Resumen de: US20260294329A1

0000 A non-invasive device for detecting Alzheimer's Disease-associated pathologies, comprising a fundus camera comprising a spectral reflectance imaging unit that includes a broadband light source and a light sensor and a lens assembly to focus light from the broadband light source onto a fundus of an eye, and one or more processors to detect reflected and/or backscattered light from the eye, illuminated by the broadband light source, using the light sensor for determining spectral reflectance information, generate a plurality of spectral reflectance maps comprising counts of reflected and/or backscattered light at a different wavelength or a different range of wavelengths, assign a weight to each of the spectral reflectance maps, and determine one or more regions of interest from the weighted spectral reflectance maps as being a potential Alzheimer's Disease-associated pathology based on a detection of one or more biomarkers indicative of Tauopathy.

METHOD FOR THE IN VITRO DIAGNOSIS OF A NEURODEGENERATIVE DISEASE

Resumen de: US20260298947A1

0000 A method for the in vitro diagnosis of a neurodegenerative disease, in a human or animal individual, at an early stage, including the step which includes in detecting the presence of at least one marker chosen from the derived forms of amyloid beta (Aβ) peptides selected from the oligomers of said peptides and the prefibrillar and fibrillar aggregated forms of said peptides, and the derived forms of phosphorylated tau proteins selected from the hyperphosphorylated forms of said proteins, the aggregated forms of said proteins and the modified phosphorylated tau proteins resulting from one or several post-translational modifications, the presence of the marker(s) being detected in a stool sample of said individual.

COMPOSITIONS AND METHODS FOR TREATING DISEASES AND CONDITIONS ASSOCIATED WITH ACTIVATION OF THE NLRP3 INFLAMMASOME

Resumen de: US20260297180A1

0000 The present invention relates to the field of inflammation. More specifically, the present invention provides compositions and methods for treating diseases and conditions associated with the priming and activation of the NLR Family Pyrin Domain Containing 3 (NLRP3) inflammasome. In particular embodiments, the method comprises the step of administering to the patient an isolated, recombinant antibody or antigen-binding fragment thereof that binds human Resistin.

SPECIMEN ANALYSIS METHOD AND SPECIMEN ANALYZER

Resumen de: US20260298958A1

Disclosed is a specimen analysis method for analyzing a specimen regarding a plurality of measurement items, the specimen analysis method comprising: measuring a first measurement item and a second measurement item on the basis of a measurement order; executing a process related to a time difference between a measurement of the first measurement item and a measurement of the second measurement item; and obtaining a calculation value from a measurement value of the first measurement item and a measurement value of the second measurement item.

METHOD FOR DETECTING ANALYTE PARTICLES PRESENT IN TRACE AMOUNTS IN FLUID SAMPLE

Resumen de: US20260298913A1

0000 The present disclosure relates to a method for detecting an analyte present in trace amounts in a fluid sample. The method includes at least: causing a fluid sample containing an analyte to flow over a substrate having an array of microchambers, with a first capture substance that specifically binds to the analyte immobilized in the microchambers; binding the analyte to the first capture substance; causing a second capture substance, which specifically binds to the analyte and binds to a signal-generating substance, to flow over the substrate; causing the signal-generating substance to flow over the substrate to bind to the second capture substance; causing a substrate solution to flow over the substrate; causing a hydrophobic solvent to flow over the substrate to remove the substrate solution present outside the microchambers; and counting and detecting the number of microchambers in which the fluorescence signal is generated.

ＴＬＲ阻害剤治療のためのバイオマーカー

Resumen de: AU2024347751A1

The present invention provides various biomarkers for identifying patients that are likely to benefit from treatment with a TLR inhibitor.

METHODS OF DETERMINING GLUCOSE HYPOMETABOLISM-INDUCED ENERGY CRISIS AND TREATMENTS THEREOF

Resumen de: WO2026207251A1

The present disclosure provides systems, methods, compositions, and algorithms for treating a subject diagnosed with a glucose hypometabolic disorder (e.g., Alzheimer's disease, Parkinson's disease, or heart failure).

METHODS OF DIAGNOSING AND TREATING NEURODEGENERATIVE DISEASE

Resumen de: WO2026206859A1

Described herein are methods and kits for the early diagnosis of neurodegenerative diseases, such as Alzheimer's disease, by detecting the enzymatic activities of L1 variants. Increased levels of the enzymatic activities serve as biological indicators that can signal the presence or risk of developing such diseases, preceding the visible or detectable changes identified by conventional techniques. Also provided herein, are methods of treating neurodegenerative diseases following early diagnosis.

PHOSPHORYLATED TAU IMMUNOASSAYS AND METHODS OF PRODUCING AND USING SAME

Resumen de: WO2026207302A1

Compositions, kits, systems, and methods for determining the presence and/or concentration of a phosphorylated Tau biomarker (such as, but not limited to, pTau217) in a biological sample and/or determining the presence of, severity of, and/or predisposition to Alzheimer's disease in an individual are disclosed. The compositions, kits, systems, and methods utilize at least two means for binding to Tau, including one means that is capable of distinguishing the phosphorylated Tau biomarker from unphosphorylated Tau, so that at least one sandwich complex can be formed. The methods include determining an amount of pTau present in the biological sample based on the amount of the sandwich immunocomplex formed.

ALPHA-SYNUCLEIN ASSAY

Nº publicación: WO2026202211A1 01/10/2026

Solicitante:

NORDIC BIOSCIENCE AS [DK]
NORDIC BIOSCIENCE A/S

Resumen de: WO2026202211A1

Methods of immunoassay are described for detecting in a patient sample (such as for example a blood, serum or plasma sample) a biomarker originating from α-Synuclein, and to the use of said methods of immunoassay for detecting and/or monitoring Parkinson's Disease or a level of severity thereof. Monoclonal antibodies and assay kits for use in said methods of immunoassay are also described.